MedTrace Logo

Study of BHV-3241 in Participants With Multiple System Atrophy

NCT03952806 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 421

Last updated 2023-09-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the efficacy of verdiperstat (BHV-3241) versus placebo in participants with Multiple System Atrophy

Conditions

Interventions

DRUG

Verdiperstat

300mg 2 oral tablets, twice daily

DRUG

Placebo

Matching placebo

Sponsors & Collaborators

  • Biohaven Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-29
Primary Completion
2021-07-29
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States
  • Austria
  • France
  • Germany
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03952806 on ClinicalTrials.gov